The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
BASF SE; Analysis of Agreement Containing Consent Orders to Aid Public Comment
0904004 Informal Interpretation
0904003 Informal Interpretation
20090350: Computershare Limited; Jonathan A. Carson
20090349: Computershare Limited; Eric S. Kurtzman
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
0904002 Informal Interpretation
20090358: Deutsche Lufthansa AG; Austrian Airlines AG
20090357: Valero Energy Corporation; VeraSun Energy Corporation
Mary T. Spohn, individually and d/b/a Herbs for Cancer, In the Matter of
20090200: BASF SE; Ciba Holding Inc.
0904001 Informal Interpretation
20090355: Gilead Sciences, Inc.; CV Therapeutics, Inc.
Bristol-Myers Squibb Company
Drug maker Bristol-Myers Squibb Company (BMS) agreed to pay $2.1 million – the largest fine allowed by law – for failing to inform the FTC of agreements reached with Apotex, Inc., regarding potential generic competition to its blockbuster drug Plavix. BMS’s conduct violated a 2003 FTC Order and the Medicare Modernization Act, which requires that certain drug company agreements be accurately reported to both the Commission and the U.S. Department of Justice. The complaint alleges that BMS failed to disclose that, as part of a patent settlement in which Apotex agreed not to launch its generic version of Plavix for several years, BMS also orally stated, among other things, that it would not compete with Apotex during the first 180 days after Apotex did market its new generic drug.